Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
| Autor: | Michael R Conroy, Alan H. Bryce, Mitesh J. Borad |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
endocrine system diseases Mutant brca1 mutation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Germline mutation Antigen medicine Genetics evofosfamide skin and connective tissue diseases investigational new drug Evofosfamide business.industry General Engineering Hypoxia (medical) medicine.disease alkylating agent 030104 developmental biology ovarian cancer chemistry Oncology 030220 oncology & carcinogenesis Cancer research medicine.symptom Ovarian cancer business th-302 DNA |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic strategies which specifically target interstrand crosslink repair can therefore be helpful in patients with harmful mutations. We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|